Sara Silbert

619 total citations · 1 hit paper
17 papers, 257 citations indexed

About

Sara Silbert is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Electrical and Electronic Engineering. According to data from OpenAlex, Sara Silbert has authored 17 papers receiving a total of 257 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 6 papers in Public Health, Environmental and Occupational Health and 3 papers in Electrical and Electronic Engineering. Recurrent topics in Sara Silbert's work include CAR-T cell therapy research (16 papers), Acute Lymphoblastic Leukemia research (6 papers) and Advancements in Semiconductor Devices and Circuit Design (3 papers). Sara Silbert is often cited by papers focused on CAR-T cell therapy research (16 papers), Acute Lymphoblastic Leukemia research (6 papers) and Advancements in Semiconductor Devices and Circuit Design (3 papers). Sara Silbert collaborates with scholars based in United States, Germany and United Kingdom. Sara Silbert's co-authors include Nirali N. Shah, Carlos A. Ramos, Renier J. Brentjens, Mohamed Abou‐El‐Enein, Leila Amini, Craig S. Sauter, Loretta J. Nastoupil, Shannon L. Maude, Bonnie Yates and Toni Foley and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Nature Reviews Clinical Oncology.

In The Last Decade

Sara Silbert

11 papers receiving 252 citations

Hit Papers

Preparing for CAR T cell therapy: patient selection, brid... 2022 2026 2023 2024 2022 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
    2022 204 citations Leila Amini, Sara Silbert et al. Nature Reviews Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sara Silbert United States 5 224 78 73 69 44 17 257
Minnal Gupta United States 7 255 1.1× 97 1.2× 73 1.0× 84 1.2× 114 2.6× 9 309
Miriam Sánchez‐Escamilla Spain 5 193 0.9× 56 0.7× 50 0.7× 66 1.0× 72 1.6× 13 239
Nathaniel Dasyam New Zealand 5 305 1.4× 104 1.3× 105 1.4× 126 1.8× 83 1.9× 8 336
Bruce L. Levine United States 4 158 0.7× 75 1.0× 27 0.4× 37 0.5× 37 0.8× 6 171
Yuehui Lin China 8 250 1.1× 53 0.7× 59 0.8× 57 0.8× 61 1.4× 27 292
Zhuojun Ling China 9 310 1.4× 64 0.8× 76 1.0× 78 1.1× 100 2.3× 20 332
Claudia Diamonte United States 10 322 1.4× 73 0.9× 84 1.2× 79 1.1× 108 2.5× 18 353
Audrey Fung United States 3 232 1.0× 79 1.0× 78 1.1× 91 1.3× 50 1.1× 3 276
Haolong Lin China 6 224 1.0× 95 1.2× 61 0.8× 95 1.4× 65 1.5× 12 270
Jinlong Xu China 6 139 0.6× 37 0.5× 41 0.6× 42 0.6× 51 1.2× 16 177

Countries citing papers authored by Sara Silbert

Since Specialization
Citations

This map shows the geographic impact of Sara Silbert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Silbert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Silbert more than expected).

Fields of papers citing papers by Sara Silbert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara Silbert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Silbert. The network helps show where Sara Silbert may publish in the future.

Co-authorship network of co-authors of Sara Silbert

This figure shows the co-authorship network connecting the top 25 collaborators of Sara Silbert. A scholar is included among the top collaborators of Sara Silbert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara Silbert. Sara Silbert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Dreyzin, Alexandra, Bonnie Yates, Haneen Shalabi, et al.. (2025). Ten-year experience of CD22 CAR T cells for children and young adults with B-cell acute lymphoblastic leukemia. Blood Advances. 10(5). 1700–1712.
2.
Valtis, Yannis K., Surabhi B Vora, Joseph M. Rocco, et al.. (2025). Pre-infusion risk factors predict severe infectious complications of CAR T-cell therapy in pediatric and adult patients with B-ALL. Journal for ImmunoTherapy of Cancer. 13(9). e012436–e012436.
3.
Peters, S., Sara Silbert, Annette Rid, et al.. (2025). How I Approach Ethical Considerations for Pediatric Phase I CAR T‐Cell Trials. Pediatric Blood & Cancer. 72(8). e31802–e31802.
4.
Silbert, Sara, Brynn B. Duncan, Bonnie Yates, et al.. (2025). Quadriparesis after CD19 × CD22 bicistronic chimeric antigen receptor T cells for B‐cell acute lymphoblastic leukaemia. British Journal of Haematology. 207(4). 1673–1678.
5.
Duncan, Brynn B., et al.. (2024). Evolving strategies for addressing CAR T-cell toxicities. Cancer and Metastasis Reviews. 44(1). 17–17. 5 indexed citations
6.
Steineck, Angela, Sara Silbert, Kelly J. Shipman, et al.. (2024). Weathering the storm when the end of the road is near: A qualitative analysis of supportive care needs during CAR T‐cell therapy in pediatrics. Pediatric Blood & Cancer. 71(9). e31092–e31092. 4 indexed citations
7.
Kovach, Alexandra E., Sara Silbert, Annie Luong, et al.. (2024). Monocytic Differentiation in B-Lymphoblastic Leukemia with CRLF2 rearrangement at Diagnosis: Implications for Pathogenesis and Post-Therapeutic Lineage Switch. Blood. 144(Supplement 1). 2799–2799.
8.
Duncan, Brynn B., Sara Silbert, Bonnie Yates, et al.. (2024). Initial Experience with CD19/CD22 BiCistronic CAR T-Cells in Children and Young Adults with Recurrent or Refractory B-Cell Malignancies. Blood. 144(Supplement 1). 680–680.
9.
Procházková, Michaela, Yihua Cai, Rongye Shi, et al.. (2024). Efficient manufacturing of CAR-T cells from whole blood: a scalable approach to reduce costs and enhance accessibility in cancer therapy. Cytotherapy. 27(3). 400–409. 3 indexed citations
10.
Silbert, Sara, Kai Rejeski, Keith Wilson, et al.. (2024). Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia. Blood. 145(11). 1136–1148. 5 indexed citations
11.
12.
Silbert, Sara, Sanna Madan, Seth M. Steinberg, et al.. (2023). A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials. Blood Advances. 7(18). 5566–5578. 2 indexed citations
13.
14.
Ligon, John A., Jacqueline Y. Maher, Toni Foley, et al.. (2022). Fertility and CAR T-cells: Current practice and future directions. Transplantation and Cellular Therapy. 28(9). 605.e1–605.e8. 20 indexed citations
15.
Amini, Leila, Sara Silbert, Shannon L. Maude, et al.. (2022). Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nature Reviews Clinical Oncology. 19(5). 342–355. 204 indexed citations breakdown →
16.
Yates, Bonnie, Sara Silbert, Toni Foley, et al.. (2022). CAR T-cells effective for post-CART relapse: A new treatment paradigm.. Journal of Clinical Oncology. 40(16_suppl). e19508–e19508. 2 indexed citations
17.
Silbert, Sara, Gregory A. Yanik, & Andrew G. Shuman. (2019). How Should We Determine the Value of CAR T-Cell Therapy?. The AMA Journal of Ethic. 21(10). E844–851. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Minnal Gupta Breakdown of academic impact, for papers by Miriam Sánchez‐Escamilla Breakdown of academic impact, for papers by Nathaniel Dasyam Breakdown of academic impact, for papers by Bruce L. Levine Breakdown of academic impact, for papers by Yuehui Lin Breakdown of academic impact, for papers by Zhuojun Ling Breakdown of academic impact, for papers by Claudia Diamonte Breakdown of academic impact, for papers by Audrey Fung Breakdown of academic impact, for papers by Haolong Lin Breakdown of academic impact, for papers by Jinlong Xu
Rankless by CCL
2026